Lowering of IOP by echothiophate iodide in pseudophakic eyes with glaucoma

K. G. Schmidt, Yosefa Horowitz, Gila Buckman, Eitan Segev, Elia Levinger, Orna Geyer*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

9 Scopus citations

Abstract

Purpose: We retrospectively investigated the intraocular pressure (IOP)-lowering effects of echothiophate iodide (EI) as adjunctive treatment for pseudophakic glaucoma patients who were receiving maximal medical therapy (MMT), including the newer class of medications, i.e., prostaglandin analogs, alpha-2 agonists, and topical carbonic anhydrase inhibitors. Methods: The medical records of all pseudophakic glaucoma patients (24 eyes) under MMT who received supplementary EI 0.125% between January 2002 and December 2003 were reviewed. IOP data and number of medications before, during and after EI treatment were collected. Results: Adding EI to MMT further reduced IOP in 23 of 24 eyes. Three eyes (12.5%) showed some lowering of IOP, but not enough to be considered controlled (IOP above the target pressure). The mean baseline IOP of 30.4±8.2 mmHg (median 29 mmHg) dropped at final follow-up (11.2±3.9 months) to 16.6±4.2 mmHg (median 17 mmHg, p<0.0001) in all eyes that had showed effective pressure reduction upon the addition of EI. Their IOP rose to 27.7±8.0 mmHg (median 28 mmHg, p<0.001) when EI was discontinued because of commercial non-availability. IOP reduction was ≥20% in 18 (75%) eyes and ≥30% (a mean decrease of 16.7±8.3mmHg) in 15 eyes (63%). Four eyes (16.6%) required a trabeculectomy despite EI supplement. Five eyes were re-challenged with EI when a small amount was released for sale: their IOP of 26.6±7.1 mmHg after the first EI discontinuation had dropped to 16.4±4.3 mmHg (p<0.0001) and rose to 29.6±7.1 mmHg when EI was again discontinued. The recorded EI-associated side effects were increased miosis in all eyes and headache (8/24 patients), neither of which were reasons for discontinuation of the drug in any patient. Conclusion: EI substantially decreased the IOPs in pseudophakic glaucoma eyes receiving maximal medical therapy, including the newer class of medications. This drug may be the last resort for post-cataract advanced glaucoma patients and may obviate the need for filtering surgery among the very elderly.

Original languageEnglish
Pages (from-to)698-702
Number of pages5
JournalCurrent Eye Research
Volume35
Issue number8
DOIs
StatePublished - Aug 2010
Externally publishedYes

Keywords

  • Adjunctive therapy
  • Echothiophate iodide
  • Glaucoma
  • Intraocular pressure
  • Pseudophakia

Fingerprint

Dive into the research topics of 'Lowering of IOP by echothiophate iodide in pseudophakic eyes with glaucoma'. Together they form a unique fingerprint.

Cite this